Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.
Anal Cancer
RADIATION: Chemo-radiotherapy with IMRT technique|DRUG: Capecitabine|DRUG: Mitomycin C
Response rate, To evaluate response rate of IMRT with chemotherapy, 8 weeks after IMRT
Adverse events, To assess the adverse events of IMRT with chemotherapy, from start of IMRT to 8 weeks after IMRT
The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.